Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The molecular and antigenic properties of a Sabin-like type 2 poliovirus, isolated from the stool samples of a 2-year-old agammaglobulinaemic child who developed paralysis 1 year after receiving the third dose of oral poliovirus vaccine, were analysed. The virus revealed 0.88 % genome variation in the VP1 region compared with the standard reference strain, compatible with replication of the virus in the intestine over approximately 1 year. The typical mutations in the 5'NCR and VP1 associated with reversion to neurovirulence for Sabin type 2 poliovirus were found. Despite this, the virus was characterized by both PCR and ELISA tests as Sabin-like and showed temperature sensitivity and neurovirulence in transgenic mice typical of the Sabin type 2 vaccine strain. Gammaglobulin replacement therapy led rapidly to virus clearance, which, when combined with treatment with the antiviral drug pleconaril, stopped virus excretion; no further virus shedding occurred. This is the first case of poliomyelitis and long-term excretion from an immunodeficient patient to be reported in Italy through the active 'Acute Flaccid Paralysis' surveillance system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The persistence of these viruses in immunocompromised individuals may compromise polio eradication efforts.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [108]
Citations
Cites
RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL
Domingo, E., & Holland, J. J. (1997) · Annual Review of Microbiology · doi:10.1146/annurev.micro.51.1.151 · Cited by 1,514 · cited 2×
“…have led to the selection of an attenuated variant, probably better adapted to replication in the gut, from a more neurovirulent virus population (Domingo & Holland, 1997); (iii) determinants that allow either high multiplication in the digestive tract or circulation of the virus do not…”
BackgroundKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 2×
“Even more worrying is the fact that VAPP outbreaks, reported recently in the Caribbean and the Philippines, have been caused by highly mutated and neurovirulent Sabin-like type 1 polioviruses (Kew et al., 2002; CDC, 2002a).”
BackgroundChronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 452
Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril
Rotbart, H. A., Webster, A. D., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373
Activity of Pleconaril against Enteroviruses
Pevear, D. C., Tull, T. M., Seipel, M. E., & Groarke, J. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2109 · Cited by 368 · cited 1×
“Pleconaril is an agent with activity against all enteroviruses (Pevear et al., 1999) and works by inhibiting the uncoating and release of infectious viral RNA, therefore blocking production of progeny virions (Rotbart, 1999).”
BackgroundHistory of Sabin attenuated poliovirus oral live vaccine strains
Sabin, A. B., & Boulger, L. R. (1973) · Journal of Biological Standardization · doi:10.1016/0092-1157(73)90048-6 · Cited by 319
Transgenic mice susceptible to poliovirus.
Koike, S., Taya, C., Kurata, T., Abe, S., Ise, I., Yonekawa, H., & Nomoto, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.951 · Cited by 294
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213 · cited 9×
“It is also important that all countries maintain high quality AFP and poliovirus surveillance and that a global strategy is developed for the cessation of immunization with OPV after global certification of polio eradication (WHO, 1997); before that, however, an adequate strategy to interrupt immunization with OPV mus…”
BackgroundInfluentialKilpatrick, D. R., Nottay, B., Yang, C. F., Yang, S. J., Mulders, M. N., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.12.2990-2996.1996 · Cited by 172
Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3001-3010.2000 · Cited by 160 · cited 2×
“In fact, a delay in the accumulation of antigenic changes in these subjects has been observed (Martin et al., 2000).”
Background
Research works printed but not linked: 5
- 2002b, Public health dispatch: poliomyelitis, Madagascar, 2002, MMWR Morb Mortal Wkly Rep, 51, 622
- Ehrenfeld, 1995, Anatomy of the poliovirus 5′ NCR, Curr Top Microbiol Immunol, 203, 165
- Fiore, 2000, & 7 other authors and the Group for the Study of AFP, Ann Ig, 12, 99
- 1997, Manual for the Virologic Investigation of Poliomyelitis
- 2001, Polio Laboratory Manual
Cited by
Antiviral peptides as promising therapeutic drugs
Vilas Boas, L. C. P., Campos, M. L., Berlanda, R. L. A., de Carvalho Neves, N., & Franco, O. L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03138-w · Cited by 336
Combelas, N., Holmblat, B., Joffret, M.-L., Colbère-Garapin, F., & Delpeyroux, F. (2011) · Viruses · doi:10.3390/v3081460 · Cited by 135
Self-citationIturriza‐Gómara, M., Megson, B., & Gray, J. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20533 · Cited by 109
Halsey, N. A., Pinto, J. A., Espinosa-Rosales, F. J., Faure-Fontenla, M. A., da Silva, E., Khan, A. J., WEBSTER, A. D. B., Minor, P. D., Dunn, G., Asturias, E. J., et al. (2004) · Europe PMC (PubMed Central) · Cited by 106
Yang, C.-F., Chen, H.-Y., Jorba, J., Sun, H.-C., Yang, S.-J., Lee, H.-C., Huang, Y.-C., Lin, T.-Y., Chen, P.-J., Shimizu, H., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12623-12634.2005 · Cited by 106
Metadata
- Authors
- Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Soresina, A. R., Vivarelli, R., Delpeyroux, F., Martin, J., & Fiore, L.
- Affiliations
- Istituto Superiore di Sanità (IT)
- University of Brescia (IT)
- University of Siena (IT)
- Epidemiologie Moleculaire des Enterovirus, Institut Pasteur, Paris, France
- NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2003-05-01
- Volume
- 84
- Issue
- 5
- Pages
- 1215-1221
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- OpenAlex
- W2101342567
- Cited by
- 73
- References
- 37
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 7
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of General Virology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- oral polio vaccine, immunodeficiency, vaccine-derived poliovirus, neurovirulence, VP1 mutations, 5' untranslated region, pleconaril, acute flaccid paralysis surveillance
- MeSH terms
- Agammaglobulinemia, Animals, Child, Preschool, Feces, Humans, Molecular Sequence Data, Poliomyelitis, Poliovirus Vaccine, Oral, Vaccines, Attenuated, Genetic Variation, Virulence, Sequence Analysis, DNA, Poliovirus, Amino Acid Substitution, 5' Untranslated Regions, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. https://app.cochat.ai/papers/10.1099/vir.0.18974-0
- The paper
- Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Soresina, A. R., Vivarelli, R., Delpeyroux, F., Martin, J., & Fiore, L. (2003). Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. Journal of General Virology. https://doi.org/10.1099/vir.0.18974-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.